

Jeffrey S Wefel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8896691/publications.pdf>

Version: 2024-02-01

118
papers

13,876
citations

53660

45
h-index

31759

101
g-index

120
all docs

120
docs citations

120
times ranked

12561
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 699-708.	13.9	2,279
2	Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. <i>Lancet Oncology</i> , The, 2009, 10, 1037-1044.	5.1	2,128
3	Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4085-4091.	0.8	820
4	Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. <i>Neuro-Oncology</i> , 2013, 15, 1429-1437.	0.6	746
5	International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. <i>Lancet Oncology</i> , The, 2011, 12, 703-708.	5.1	717
6	The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. <i>Cancer</i> , 2004, 100, 2292-2299.	2.0	630
7	Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1487-1495.	0.4	611
8	Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. <i>Cancer</i> , 2010, 116, 3348-3356.	2.0	409
9	Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 123-138.	157.7	368
10	Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 895-902.	0.8	366
11	Chemobrain™ in breast carcinoma?. <i>Cancer</i> , 2004, 101, 466-475.	2.0	313
12	Chemotherapy-Related Cognitive Dysfunction. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 267-275.	2.0	302
13	The Use of the Mini-Mental State Examination to Assess Cognitive Functioning in Cancer Trials: No Ifs, Ands, Buts, or Sensitivity. <i>Journal of Clinical Oncology</i> , 2003, 21, 3557-3558.	0.8	232
14	A PILOT STUDY OF NEUROCOGNITIVE FUNCTION IN PATIENTS WITH ONE TO THREE NEW BRAIN METASTASES INITIALLY TREATED WITH STEREOTACTIC RADIOSURGERY ALONE. <i>Neurosurgery</i> , 2007, 60, 277-284.	0.6	166
15	Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?. <i>Journal of Clinical Oncology</i> , 2018, 36, 483-491.	0.8	151
16	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016, 34, 945-952.	0.8	148
17	A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. <i>Journal of Neuro-Oncology</i> , 2012, 107, 165-174.	1.4	138
18	ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. <i>Clinical Cancer Research</i> , 2020, 26, 2789-2799.	3.2	130

#	ARTICLE	IF	CITATIONS
19	Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. <i>Journal of Pain and Symptom Management</i> , 2015, 50, 830-841.	0.6	125
20	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e407-e416.	5.1	119
21	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e396-e406.	5.1	116
22	Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. <i>Neuro-Oncology</i> , 2015, 17, 580-587.	0.6	115
23	Neuropsychological Sequelae of Non-Central Nervous System Cancer and Cancer Therapy. <i>Neuropsychology Review</i> , 2008, 18, 121-131.	2.5	113
24	Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4076-4084.	0.8	110
25	Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. <i>Neuro-Oncology</i> , 2016, 18, 1656-1663.	0.6	110
26	A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. <i>Neuro-Oncology</i> , 2008, 10, 208-215.	0.6	109
27	Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11600-11605.	3.3	106
28	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011, 13, 353-361.	0.6	105
29	Neurocognitive function before and after surgery for insular gliomas. <i>Journal of Neurosurgery</i> , 2011, 115, 1115-1125.	0.9	97
30	Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 808-816.	0.6	96
31	Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011, 13, 660-668.	0.6	94
32	The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. <i>Lancet</i> , The, 2022, 399, 1886-1901.	6.3	89
33	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e20-e32.	5.1	87
34	Cognitive Changes in Cancer Survivors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 795-806.	1.8	79
35	Cognitive impairment in men with testicular cancer prior to adjuvant therapy. <i>Cancer</i> , 2011, 117, 190-196.	2.0	62
36	A review of prostate cancer treatment impact on the CNS and cognitive function. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 207-219.	2.0	59

#	ARTICLE	IF	CITATIONS
37	CODEL: phase III study of RT, RT+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. <i>Neuro-Oncology</i> , 2021, 23, 457-467.	0.6	58
38	The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 565-574.	1.4	57
39	A prospective study of cognitive function in men with non-seminomatous germ cell tumors. <i>Psycho-Oncology</i> , 2014, 23, 626-633.	1.0	54
40	Neurocognitive functioning in patients with glioma of the left and right temporal lobes. <i>Journal of Neuro-Oncology</i> , 2016, 128, 323-331.	1.4	54
41	Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. <i>Cancer</i> , 2013, 119, 4188-4195.	2.0	53
42	Neurocognitive functioning and genetic variation in patients with primary brain tumours. <i>Lancet Oncology</i> , The, 2016, 17, e97-e108.	5.1	51
43	A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1337-1347.	0.6	50
44	Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma. <i>Psycho-Oncology</i> , 2017, 26, 617-624.	1.0	47
45	TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. <i>Aging</i> , 2016, 8, 3507-3519.	1.4	47
46	Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma. <i>Neurosurgery</i> , 2015, 77, 777-785.	0.6	46
47	Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons. <i>Scientific Reports</i> , 2016, 6, 25705.	1.6	43
48	Improvement of Sleep Disturbance and Neurocognitive Function after Parathyroidectomy in Patients with Primary Hyperparathyroidism. <i>Endocrine Practice</i> , 2007, 13, 338-344.	1.1	42
49	Course of Cognitive Decline in Hematopoietic Stem Cell Transplantation: A Within-subjects Design. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 689-698.	0.3	42
50	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e33-e42.	5.1	42
51	Chemotherapy-related changes in cognitive functioning. <i>European Journal of Cancer</i> , Supplement, 2013, 11, 225-232.	2.2	41
52	Cognitive and affective sequelae of primary hyperparathyroidism and early response to parathyroidectomy. <i>Journal of the International Neuropsychological Society</i> , 2009, 15, 1002-1011.	1.2	37
53	Nonpharmacological interventions for cancer-related cognitive impairment in adult cancer patients: A network meta-analysis. <i>International Journal of Nursing Studies</i> , 2020, 104, 103514.	2.5	36
54	Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. <i>Molecular and Cellular Neurosciences</i> , 2018, 86, 65-71.	1.0	35

#	ARTICLE	IF	CITATIONS
55	Depressive symptoms and executive function in relation to survival in patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 183-191.	1.4	35
56	Functional Outcomes and Health-Related Quality of Life Following Glioma Surgery. <i>Neurosurgery</i> , 2021, 88, 720-732.	0.6	35
57	Chemotherapy and Cognition: Effects, Potential Mechanisms, and Management. <i>American Journal of Therapeutics</i> , 2006, 13, 362-369.	0.5	34
58	Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. <i>Brain Imaging and Behavior</i> , 2013, 7, 501-510.	1.1	31
59	Interventions for cognitive problems in adults with brain cancer: A narrative review. <i>European Journal of Cancer Care</i> , 2019, 28, e13088.	0.7	31
60	Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?. <i>Nature Reviews Neurology</i> , 2022, 18, 173-185.	4.9	31
61	Genetic Modulation of Neurocognitive Function in Glioma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3340-3346.	3.2	29
62	Congruence of primary brain tumor patient and caregiver symptom report. <i>Cancer</i> , 2012, 118, 5026-5037.	2.0	27
63	Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. <i>Neuro-Oncology</i> , 2016, 18, ii13-ii20.	0.6	27
64	Relationship between cognitive function and prognosis in glioblastoma. <i>CNS Oncology</i> , 2013, 2, 195-201.	1.2	24
65	Neurocognitive functioning is associated with functional independence in newly diagnosed patients with temporal lobe glioma. <i>Neuro-Oncology Practice</i> , 2018, 5, 184-193.	1.0	22
66	Cancer as a Risk Factor for Dementia: A House Built on Shifting Sand. <i>Journal of the National Cancer Institute</i> , 2005, 97, 788-789.	3.0	21
67	Neurocognitive aspects of brain metastasis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 155-165.	1.0	21
68	Neuropsychological Practice in the Oncology Setting. <i>Archives of Clinical Neuropsychology</i> , 2018, 33, 344-353.	0.3	21
69	Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 132, 181-188.	1.4	16
70	Neurocognitive Function in Adult Cancer Patients. <i>Neurologic Clinics</i> , 2018, 36, 653-674.	0.8	15
71	Monitoring of Neurocognitive Function in the Care of Patients with Brain Tumors. <i>Current Treatment Options in Neurology</i> , 2019, 21, 33.	0.7	14
72	Neurocognitive dysfunction in adult cerebellar medulloblastoma. <i>Psycho-Oncology</i> , 2019, 28, 131-138.	1.0	12

#	ARTICLE	IF	CITATIONS
73	Verbal Learning Processes in Patients with Glioma of the Left and Right Temporal Lobes. Archives of Clinical Neuropsychology, 2016, 31, 37-46.	0.3	10
74	Alterations in Functional Connectomics Associated With Neurocognitive Changes Following Glioma Resection. Neurosurgery, 2021, 88, 544-551.	0.6	10
75	Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRC/RTOG 0825). Neuro-Oncology, 2021, 23, 1125-1138.	0.6	10
76	Cognitive Impairment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 603-603.	0.6	10
77	Silent Sentence Completion Shows Superiority Localizing Wernicke's Area and Activation Patterns of Distinct Language Paradigms Correlate with Genomics: Prospective Study. Scientific Reports, 2017, 7, 12054.	1.6	9
78	The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. Neuro-Oncology Practice, 2019, 6, 274-282.	1.0	9
79	Language supplementary motor area syndrome correlated with dynamic changes in perioperative task-based functional MRI activations: case report. Journal of Neurosurgery, 2021, 134, 1738-1742.	0.9	8
80	Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors. Hematology/Oncology Clinics of North America, 2022, 36, 269-282.	0.9	8
81	Editorial: Post-traumatic Stress as the Primary Cause for Cognitive Decline" Not the Whole Story, and Perhaps No Story at All. Journal of the National Cancer Institute, 2017, 109, .	3.0	7
82	Association of genetic variants with fatigue in patients with malignant glioma. Neuro-Oncology Practice, 2018, 5, 122-128.	1.0	7
83	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. Neurosurgery, 2019, 84, 66-76.	0.6	7
84	Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neuro-Oncology Advances, 2021, 3, vdab079.	0.4	6
85	Preservation of neurocognitive function in the treatment of brain metastases. Neuro-Oncology Advances, 2021, 3, v96-v107.	0.4	6
86	Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors. CNS Drugs, 2022, 36, 419-449.	2.7	6
87	Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. Head and Neck, 2017, 39, 2048-2056.	0.9	5
88	Impaired neurocognitive function in glioma patients: from pathophysiology to novel intervention strategies. Current Opinion in Neurology, 2020, 33, 716-722.	1.8	5
89	Systemically Treated Breast Cancer Patients and Controls: An Evaluation of the Presence of Noncredible Performance. Journal of the International Neuropsychological Society, 2014, 20, 357-369.	1.2	4
90	Comparison of time trade-off utility with neurocognitive function, performance status, and quality of life measures in patients with metastatic brain disease. Journal of Radiation Oncology, 2014, 3, 215-221.	0.7	3

#	ARTICLE	IF	CITATIONS
91	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab035.	0.4	3
92	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2014, 32, 1634-1635.	0.8	2
93	Driver safety in patients with primary brain tumors. <i>Neuro-Oncology Practice</i> , 2019, 6, 490-498.	1.0	2
94	Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients. <i>Journal of Neuro-Oncology</i> , 2022, 156, 185-193.	1.4	2
95	RESPONSE: Re: Cancer as a Risk Factor for Dementia: A House Built on Shifting Sand. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1551-1552.	3.0	1
96	Whole-brain irradiation for patients with brain metastases: still the standard of care – Authors' reply. <i>Lancet Oncology</i> , The, 2010, 11, 223.	5.1	1
97	Reply to Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. <i>Cancer</i> , 2011, 117, 1103-1104.	2.0	1
98	Cancer neurology, neuro-oncology, and clinical decision making. <i>Neuro-Oncology Practice</i> , 2015, 2, 159-160.	1.0	1
99	Response to “From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function”. <i>Neuro-Oncology</i> , 2015, 17, 1421-1422.	0.6	1
100	Phase II Trial of Proton Therapy vs. Photon IMRT for GBM: Secondary Analysis Comparison of Progression Free Survival between RANO vs. Clinical Assessment. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab073.	0.4	1
101	Cognitive Rehabilitation in Patients with Non-Central Nervous System Cancers and Brain Tumors. , 2020, , 221-254.		1
102	Lessons learned from proton vs photon radiation therapy for glioblastoma signal-finding trial. <i>Neuro-Oncology</i> , 2022, 24, 851-851.	0.6	1
103	Neuropsychological Assessment of Older Adults with a History of Cancer. , 2013, , 443-454.		0
104	Neuro-Oncology Practice: Time Flies When You Are Having Fun!. <i>Neuro-Oncology Practice</i> , 2014, 1, 143-144.	1.0	0
105	NCOG-17. EVALUATION OF NEUROCOGNITIVE FUNCTION IN PATIENTS WITH CEREBELLAR MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi123-vi123.	0.6	0
106	Neuro-Oncology Practice: Learning from our past to guide our future. <i>Neuro-Oncology Practice</i> , 2016, 3, 209-210.	1.0	0
107	Reply to Freyschlag et al. <i>Neuro-Oncology</i> , 2017, 19, 598-599.	0.6	0
108	Choosing clinical trial endpoints, aggregating data, and making clinical decisions. <i>Neuro-Oncology Practice</i> , 2017, 4, 199-200.	1.0	0

#	ARTICLE	IF	CITATIONS
109	Patient-centered care in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2018, 5, 1-1.	1.0	0
110	Food for thought: patient outcomes, diagnostic challenges, and therapeutic possibilities. <i>Neuro-Oncology Practice</i> , 2018, 5, 203-203.	1.0	0
111	Opportunities to enhance our management, outcomes, and interventions for patients with CNS malignancy. <i>Neuro-Oncology Practice</i> , 2019, 6, 247-248.	1.0	0
112	Improving access and standard of care for all. <i>Neuro-Oncology Practice</i> , 2020, 7, 261-262.	1.0	0
113	In Reply: Functional Outcomes and Health-Related Quality of Life Following Glioma Surgery. <i>Neurosurgery</i> , 2021, 89, E189-E189.	0.6	0
114	Short reply to "Proton therapy for newly diagnosed glioblastoma: More room for investigation" by R. Press et al. <i>Neuro-Oncology</i> , 2021, 23, 1982.	0.6	0
115	Neuropsychological Assessment of Older Adults with a History of Cancer. <i>Clinical Handbooks in Neuropsychology</i> , 2019, , 427-442.	0.1	0
116	Neurocognitive Toxicity from Radiation Therapy for Brain Metastases. , 2020, , 315-328.		0
117	Neurocognitive Effects of Brain Metastases and Their Treatment. , 2020, , 407-425.		0
118	Measuring Everyday Functioning in Brain Tumor Patients: The Long Rows Yet to Hoe. <i>Neuro-Oncology Practice</i> , 0, , .	1.0	0